Replies to post #4665 on IR-Med Inc. (IRME)

[Walker]

More info on BCLI Funding -

https://www.crunchbase.com/organization/brainstorm-cell-therapeutics#section-overview

Total Funding Amount
$36.5M
CB Rank (Company)
15,863

BrainStorm Cell Therapeutics is a biotechnology company developing autologous stem cell therapies for neurodegenerative diseases.
New York, New York, United States
Categories
Biotechnology, Health Care, Medical, Therapeutics
Headquarters Regions
Greater New York Area, East Coast, Northeastern US
Founded Date
2004
Founders
Daniel Offen
Operating Status
Active
Funding Status
IPO
Last Funding Type
Grant
Number of Employees
11-50
Legal Name
Brainstorm Cell Therapeutics Ltd.
IPO Status
Public
Stock Symbol
NASDAQ:BCLI
Website
www.brainstorm-cell.com
Facebook
View on Facebook
LinkedIn
View on LinkedIn
Twitter
View on Twitter
Contact Email
[e-mail]
Phone Number
646-666-3188
BrainStorm Cell Therapeutics (OTC.QB: BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).

NurOwn™ , our proprietary, first-of-its-kind technology for the propagation and differentiation of autologous Mesenchymal Stem Cells (MSCs) into NeuroTrophic Factor (NTF)-secreting cells and their transplantation at or near the site of damage, offers the hope of conquering neurodegenerative diseases.

We are currently conducting a Phase IIa ALS clinical trial with NurOwn at the Hadassah University Medical Center in Jerusalem. In this safety and preliminary efficacy trial, 12 patients will receive combined intramuscular and intrathecal administration of NurOwn cells in three cohorts with increasing doses. The study participants will be followed for three to six months after transplantation.

The company also plans to begin a Phase II clinical trial in the USA in 2013, pending FDA approval.

In February 2011, NurOwn was granted Orphan Drug designation by the FDA.

Over 20 publications in leading scientific journals demonstrating NurOwn's mechanism of action, pharmacology and in vivo efficacy have been published by the scientific team.